Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

345.76
BATS BZX Real-Time Price
As of 1:57pm ET
 +5.30 / +1.56%
Today’s Change
281.89
Today|||52-Week Range
442.00
-7.43%
Year-to-Date
Crossvault Capital Management LLC Buys Regeneron Pharmaceuticals Inc, Square Inc, Net...
Apr 24 / GuruFocus News - Paid Partner Content
Is Alnylam Pharmaceuticals a Buy Now?
Apr 16 / MotleyFool.com - Paid Partner Content
Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
Apr 16 / Zacks.com - Paid Partner Content
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
Apr 15 / Zacks.com - Paid Partner Content
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
Apr 16 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close340.46
Today’s open339.11
Day’s range338.08 - 346.12
Volume320,106
Average volume (3 months)754,367
Market cap$35.8B
Data as of 1:57pm ET, 04/25/2019

Growth & Valuation

Earnings growth (last year)+100.98%
Earnings growth (this year)+0.98%
Earnings growth (next 5 years)+11.00%
Revenue growth (last year)+14.28%
P/E ratio16.2
Price/Sales6.39
Price/Book4.15

Competitors

 Today’s
change
Today’s
% change
BAXBaxter International...-0.61-0.80%
ALXNAlexion Pharmaceutic...+1.69+1.30%
VRTXVertex Pharmaceutica...+1.25+0.72%
AGNAllergan+1.00+0.72%
Data as of 1:57pm ET, 04/25/2019

Financials

Next reporting dateMay 7, 2019
EPS forecast (this quarter)$5.41
Annual revenue (last year)$6.7B
Annual profit (last year)$2.4B
Net profit margin36.42%

Profile

Sector
Health Technology
Industry
Biotechnology
Co-President, Chief Executive Officer &
Director
Leonard S. Schleifer
Co-President, Director &
Chief Scientific Officer
George Damis Yancopoulos
Corporate headquarters
Tarrytown, New York

Forecasts